Impact of Venous Thromboembolism on Mortality of Elderly Medicare Patients with Stage III Colon Cancer

Abstract

After completing this course, the reader will be able to:1. Identify the prevalence of adjuvant chemotherapy utilization in elderly patients with stage III colon cancer.2. Discuss the prevalence and impact of venous thromboembolism in elderly patients with stage III colon cancer.3. Identify potential for development of a clinical trial to study the clinical benefit and impact on cancer-specific and all-cause mortality of thromboprophylaxis during adjuvant chemotherapy in elderly patients with stage III colon cancer.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTBackground. The improvement in survival rates for patients with colon cancer has shifted the focus from examining cancer-specific mortality to exploring all-cause mortality. Adverse events such as venous thromboembolism (VTE) affect overall survival times and the net clinical benefit of cancer management strategies.Methods. This retrospective study used Surveillance, Epidemiology and End Results (SEER) Medicare data to examine VTE incidence and mortality rates for elderly

Overall Survival, Costs and Healthcare Resource Use by Number of Regimens Received in Elderly Patients with Newly Diagnosed Metastatic Triple-Negative Breast Cancer

“…Baseline comorbidities of the study sample were measured based on the Deyo and Romano adaptation of the Charlson Comorbidity Index (CCI) using Medicare claims. A proxy measure for poor performance status was created and defined as any claim in the baseline period for wheelchair use, oxygen use, walking aid, hospital bed, hospice, skilled nursing facility or hospitalization [21][22][23][24]. Baseline cancer and clinical characteristics assessed included diagnosis year, topographic location of tumor, tumor size and laterality.…”

Occurrence and Prognosis of Symptomatic Venous Thromboembolism in Colorectal Cancer Surgery Patients

“…In our study, the factors which affected the incidence of VTE were histologic subtype (mucinous adenocarcinoma) and previous VTE history. Other study showed that cancer stage and VTE history were factors affecting the occurrence of DVT and PE in CRC patients after surgery [ 17 ]. However, the number of patients with VTE in our study was small, limiting the analysis of factors affecting the occurrence of DVT and PE.…”

Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations

“…Patients with cancer have a six-to sevenfold higher risk of VTE than those without [1]. Progressing cancers account for almost 20 % of all new VTE cases [2], and the occurrence of VTE increases the risk of death in cancer patients (hazard ratios, 1.6-4.2; P < 0.01) [3,4]. According to Geerts et al, Cancer patients who undergo surgery have a risk of developing postoperative DVT two times higher than non-cancer patients, and three times more likely to make a fatal PE [5].…”

“…The risk of VTE varies according to both tumor type and location [1][2][3][4][5][6][7][8]. With an odds ratio (OR) of 28.0 (95 % CI 4.0-199.7), hematologic cancers are associated with the highest risk, followed by lung cancers (OR=22.2; 95 % CI 3.6-136.1), and gastrointestinal cancers (OR=20.3; 95 % CI 4.9-83.0), while breast cancer patients have a much lower risk of VTE (OR=4.9; 95 % CI 2.3-10.5) [9].…”